In collaboration with our partner CPI (UK), we have successfully developed non-toxic ambient temperature liquid-stable mRNA-LNP formulations that significantly improve stability, potency and pharmacokinetics. Our pioneering TheraPHIX™ stabilization technology extends the shelf-life of mRNA vaccines and therapeutics, reducing transportation costs and energy consumption. Our innovation ensures broader distribution and greater accessibility, preparing us to better tackle future health challenges.